Yantai Dongcheng Beifang Pharmaceutical Co.,Ltd

Yantai Dongcheng Beifang Pharmaceutical Co., Ltd., established in February 1993 and located in Dongcheng Pharmaceutical Industrial Park of Yantai Economic and Technological Development Zone, has the registered capital of RMB50 million. In 2002, the company became a wholly-owned subsidiary of Yantai Dongcheng Pharmaceutical Group Co., Ltd. In May 2012, Yantai Dongcheng Pharmaceutical Group Co., Ltd. successfully became a public listed company.

Currently, Yantai Dongcheng Beifang Pharmaceutical Co., Ltd. mainly produces the lyophilized powder injections, with a total of 17 varieties and more than 30 approval numbers. Its main product nadroparin calcium for injection (trade name: Bailishu) has become a leading brand of low molecular weight heparin preparations in China, with the sales revenue of more than RMB600 million in 2019.

The company has over 150 employees now, of which 80% are college graduates or above. With the quality as the guarantee, supported by talents, oriented by the market, the company strives to make outstanding contributions on the new journey of “second business startup” of Dongcheng Pharmaceutical.